Annandale Capital’s Aptose Biosciences, Inc. APTO Stock Holding History

Annandale Capital’s Portfolio APTO Stock Details APTO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-889	Closed	-$6K	–	140
2024 Q4	$6K	Hold	889	–	–	﹤0.01%	128
2024 Q3	$11K	Buy	+889	New	+$13.5K	﹤0.01%	128
2024 Q2	–	Sell	-889	Closed	-$44K	–	148
2024 Q1	$44K	Sell	889 -1,600	-64%	-$91.5K	0.01%	135
2023 Q4	$188K	Hold	2,489	–	–	0.04%	131
2023 Q3	$209K	Buy	2,489 +711	+40%	+$83.8K	0.05%	112
2023 Q2	$247K	Hold	1,778	–	–	0.07%	113
2023 Q1	$513K	Hold	1,778	–	–	0.16%	88
2022 Q4	$464K	Buy	1,778 +200	+13%	+$53.7K	0.15%	93
2022 Q3	$422K	Buy	1,578 +709	+82%	+$244K	0.16%	90
2022 Q2	$290K	Buy	869 +425	+96%	+$203K	0.11%	108
2022 Q1	$272K	Buy	+444	New	+$246K	0.11%	96

Other funds holding APTO

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SPC

Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northwestern Mutual Wealth Management Milwaukee, Wisconsin $162B AUM 16.35% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Gleason Group Prospect, Kentucky $1.15B AUM 21.11% 1-Year Est. Return

NFSG

Newbridge Financial Services Group Boca Raton, Florida $608M AUM 31.28% 1-Year Est. Return

Annandale Capital's APTO Position: Q1 2025 in Review

Annandale Capital sold out of Aptose Biosciences, Inc. (APTO) in Q1 2025, closing a stake of 889 shares — an estimated $6K sold.

Annandale Capital first reported a position in APTO in Q1 2022 and held it in 11 quarters. The position peaked at $513K in Q1 2023. 16 funds tracked by Wall St. Rank hold APTO as of Q1 2025.

Annandale Capital reported no remaining Aptose Biosciences, Inc. position as of Q1 2025 after selling out during the quarter.
Annandale Capital sold 889 Aptose Biosciences, Inc. shares in Q1 2025, an estimated $6K.
Annandale Capital first reported a position in Aptose Biosciences, Inc. in Q1 2022 and held it in 11 quarters.
Annandale Capital's Aptose Biosciences, Inc. position peaked at $513K in Q1 2023.
16 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2025.

Based on Annandale Capital's 13F filing for Q1 2025, filed 13 May 2025.